Capital Analysts, LLC Clovis Oncology, Inc. Transaction History

Capital Analysts, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$4.13 - $6.41 $72,275 - $112,175	-17,500 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$4.82 - $7.72 $4,820 - $7,720	1,000 Added 6.06%	17,500 $102,000
Q2 2020 Aug 07, 2020	SELL	$5.69 - $9.69 $5,690 - $9,690	-1,000 Reduced 5.71%	16,500 $111,000
Q1 2020 May 08, 2020	BUY	$3.77 - $11.0 $3,475 - $10,142	922 Added 5.56%	17,500 $111,000
Q4 2019 Feb 12, 2020	BUY	$3.0 - $16.43 $18,984 - $103,969	6,328 Added 61.74%	16,578 $173,000
Q3 2019 Nov 12, 2019	BUY	$3.93 - $15.35 $4,421 - $17,268	1,125 Added 12.33%	10,250 $40,000
Q2 2019 Aug 13, 2019	BUY	$12.81 - $25.67 $12,810 - $25,670	1,000 Added 12.31%	9,125 $136,000
Q1 2019 May 13, 2019	BUY	$17.66 - $30.28 $130,242 - $223,315	7,375 Added 983.33%	8,125 $201,000
Q4 2018 Feb 13, 2019	BUY	$11.63 - $32.67 $5,815 - $16,335	500 Added 200.0%	750 $13,000
Q3 2018 Nov 07, 2018	SELL	$29.37 - $49.48 $26,433 - $44,532	-900 Reduced 78.26%	250 $0
Q2 2018 Aug 03, 2018	BUY	$42.06 - $62.4 $24,184 - $35,880	575 Added 100.0%	1,150 $0
Q1 2018 May 14, 2018	BUY	$50.12 - $67.72 $16,289 - $22,009	325 Added 130.0%	575 $30,000
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $25,960 - $38,061	-450 Reduced 64.29%	250 $17,000
Q4 2017 Feb 12, 2018	SELL	$57.69 - $84.58 $37,498 - $54,977	-650 Reduced 48.15%	700 $10,000
Q3 2017 Nov 06, 2017	BUY	$67.17 - $84.81 $90,679 - $114,493	1,350	1,350 $111,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Capital Analysts, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Analysts, LLC with notifications on news.